Not exact matches
Richard Hargreaves, executive director of imaging at Merck Research Laboratories, says, «Nuclear imaging using radiotracers gives the opportunity to put your
arms around proof - of - concept very early in a drug discovery and development program by focusing the selection of
doses to
study on those proven to deliver enough drug to the target therapeutic sites.»
Despite the small size of the
study, the authors were confident that the low -
dose arm was comparable to the standard
dose.
Additionally, I predict that at the completion of our
study, despite the higher
doses given per treatment in the experimental accelerated, hypofractionated RT
arm, there will be no increased toxicity with this regimen.
Fewer adverse events were observed in the RBV - free, fixed -
dose combination
arms compared to the RBV - containing
arms in all the ION
studies.
The SCiStar
study is an open - label, single -
arm trial testing three sequential escalating
doses of AST - OPC1 administered at up to 20 million AST - OPC1 cells in 25 subjects with subacute motor complete (AIS - A or AIS - B) cervical (C - 4 to C - 7) spinal cord injury.
In another
arm of the
study, breast cancer patients took a single
dose of sulforaphane and measurable amounts of the compound were detected in the women's breast tissue following the
dose.
The present
study, with its efficacious
dose,
arms physicians with data to tell patients who have not had an MI and who don't have heart failure that n - 3 fatty acid supplementation with fish oil is not effective.
One
study using a daily 2.5 gram
dose of Betaine (the
dose found in NITROSURGE (per 2 scoops *)-RRB- resulted in a 4 lb lean muscle gain, 7 lb fat loss, and a 10 % increase in
arm size in just 6 weeks.